上会确定！第五套标准重启后首单！

Core Viewpoint - Wu Yuan Bio is the first company to be reviewed under the newly established fifth set of standards for the Sci-Tech Innovation Board, following the announcement of support for unprofitable companies to list [1][7]. Company Overview - Wu Yuan Bio, established in 2006, focuses on innovative drug research and development, with its core product HY1001 (recombinant human albumin injection) having completed Phase III clinical trials and included in the priority review process by the National Medical Products Administration [3][4]. - The company has not yet generated revenue from its core innovative drug products, with current income primarily from pharmaceutical excipients and research reagents [3][6]. - Cumulative R&D investment from 2022 to 2024 is projected to reach 386 million yuan, with a workforce of 178 employees, 122 of whom are dedicated to R&D, indicating a strong focus on innovation [3][6]. Product Development - HY1001 aims to supplement or enhance the levels of human serum albumin in the blood, potentially replacing plasma-derived human serum albumin, which is currently the most widely used blood product in clinical settings [3][4]. - The company has achieved breakthroughs in increasing the expression and purity of recombinant human albumin, reducing production costs, and enhancing clinical safety, earning a second-class National Technology Invention Award for its related technology [4]. Industry Context - As of 2024, 20 companies have been listed under the fifth set of standards, primarily consisting of innovative biopharmaceutical firms, with a combined revenue exceeding 14 billion yuan, reflecting a growth of over 40% from 2023 [6][7]. - In the first quarter of 2025, these companies collectively achieved a revenue of 3.78 billion yuan, marking a year-on-year growth of 29.27% [7]. - The fifth set of standards has facilitated the listing of 17 first-class new drugs, accounting for approximately 12% of the total number of domestically approved innovative drugs from 2018 to the first quarter of 2025, establishing itself as a backbone of China's pharmaceutical innovation [7].